Table 1.
Characteristics of study participants in the SCI group.
| Patient | AIS | Neurological level of injury | Time since injury | Age range | Medication |
|---|---|---|---|---|---|
| 1 | A | C4 | >15 years | 35–39 | a, b, d, e |
| 2 | B | C6 | 3–6 months | 20–24 | a |
| 3 | A | Th6 | 6–12 months | 25–29 | c, d, e |
| 4 | A | Th7 | 6–12 months | 20–25 | a, e |
| 5 | A | C6 | >15 years | 45–49 | – |
| 6 | D | L1 | 3–6 months | 20–24 | – |
| 7 | A | Th6 | 6–12 months | 35–39 | a, c, d, e |
| 8 | A | C4 | >5 years | 20–24 | a |
| 9 | B | C5 | 3–6 months | 18–19 | a, b, c, e |
| 10 | A | Th10 | 3–6 months | 45–49 | a |
| 11 | A | C6 | > 15 years | 35-39 | d, e |
CNS effective medication are categorized into “a” (opioids), “b” (benzodiazepines), “c” (anticonvulsants), “d” (spasmolytics), and “e” (anticholinergics). AIS, American Spinal Injury Association (ASIA) Impairment Scale. Ranges are given for time since injury and age to exclude any potential identification of subjects.